Fresenius launches €200M venture fund to chase healthcare innovation
What's the deal? Fresenius has set up a corporate venture capital fund with an intended investment volume of more than €200 million over the next five years. The new unit, Fresenius Ventures, will back founders, technologies, and business models from early financing rounds through to growth stage.
What's the endgame? The fund targets growth fields adjacent to Fresenius' existing platforms in (bio)pharma, MedTech, and care provision. Investment areas include precision nutrition, microbiome research, new modalities, and digital care solutions.
Who's leading it? Thomas Michael Thestrup joins as managing director and head of Fresenius Ventures. He arrives from Angelini VenturesDealroom has a profile for this one. Try Dealroom →, the healthcare venture arm of Italian industrial group Angelini IndustriesDealroom has a profile for this one. Try Dealroom →.
Why now? Chief executive officer Michael Sen framed the fund as "a strategic instrument of #FutureFresenius," the group's ongoing transformation programme. The goal is early access to breakthrough technologies and entrepreneurial talent across the healthcare ecosystem.
The unit pairs capital with medical, regulatory, and operational expertise, plus access to clinical, scientific, and academic networks. Investments will follow Fresenius' capital allocation approach.
What Fresenius says: "We offer more than capital: deep operating and regulatory expertise across global markets, coupled with access to the clinical, scientific, and academic ecosystems where real progress happens today," Thestrup said.
The signal: Fresenius joins a growing list of healthcare incumbents building in-house venture arms to stay close to innovation they cannot always develop internally. By investing in adjacent fields such as microbiome research and digital care, the group is betting on where medicine — and its own future revenue — may be headed.
Read more: wallstreet-online.de
Image credit: Generated with Gemini
